Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases - Intercept Pharmaceuticals, Inc.
ir.interceptpharma.comSubmitted by interceptpharmacom4903 in business
The Investor Relations website contains information about Intercept Pharmaceuticals, Inc.'s business for stockholders, potential